Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Flutamide |
Synonyms | |
Therapy Description |
Eulexin (flutamide) is a nonsteroidal antiandrogen that competitively blocks androgen receptors. Eulexin prevents receptor activation and translocation to the nucleus, thus preventing androgen-dependent DNA and protein synthesis, which may prevent tumor cell growth (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Flutamide | Eulexin | Flutamide USP25 | Hormone - Anti-androgens 54 | Eulexin (flutamide) is a nonsteroidal antiandrogen that competitively blocks androgen receptors. Eulexin prevents receptor activation and translocation to the nucleus, thus preventing androgen-dependent DNA and protein synthesis, which may prevent tumor cell growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00936390 | Phase III | Flutamide Goserelin Leuprolide Triptorelin Bicalutamide | Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer | Active, not recruiting | USA | CAN | 0 |
NCT00223665 | Phase II | Leuprolide Flutamide | Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy | Completed | USA | 0 |
NCT05050084 | Phase III | Buserelin Relugolix Degarelix Goserelin Leuprolide Histrelin acetate Triptorelin Darolutamide + Goserelin Bicalutamide Darolutamide + Degarelix Darolutamide + Leuprolide Darolutamide + Triptorelin Buserelin + Darolutamide Darolutamide + Histrelin acetate Flutamide Darolutamide + Relugolix | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | Recruiting | USA | CAN | 0 |
NCT02799706 | Phase III | Flutamide Degarelix Bicalutamide | Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer (PEGASUS) | Active, not recruiting | ITA | GBR | FRA | ESP | DNK | DEU | CHE | BEL | 0 |
NCT03678025 | Phase III | Docetaxel Nilutamide Triptorelin Bicalutamide Leuprolide Degarelix Goserelin Flutamide Prednisone Abiraterone Histrelin acetate | Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Recruiting | USA | CHE | 3 |
NCT04787744 | Phase II | Goserelin Degarelix Relugolix Nilutamide Triptorelin Histrelin acetate Docetaxel + Prednisone Leuprolide Apalutamide Abiraterone + Prednisone Flutamide Abiraterone + Methylprednisolone Bicalutamide Docetaxel Enzalutamide | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (VA STARPORT) | Recruiting | USA | 0 |
NCT03507608 | Phase I | Flutamide | Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression | Active, not recruiting | USA | 0 |